Back to search results

Understanding Heart Changes After Cancer Treatment

This study is looking into why some cancer patients develop heart problems after receiving treatments like chemotherapy or immunotherapy. Researchers will collect blood samples and review medical records from people who have experienced heart issues related to their cancer treatment, or those who are at high risk for developing them. The goal is to identify factors that predict these heart problems. You may be able to join if you are 18 or older, have been treated for cancer with chemotherapy or immunotherapy, and have either been diagnosed with a heart condition like cardiomyopathy (a disease of the heart muscle) or heart failure, or are at high risk for developing one. This is an observational study, meaning you won't receive any new treatments as part of the study.

Study design
This is an observational study aiming to enroll 1000 participants. It is not a treatment study.
What's involved
You would provide blood samples and allow researchers to review your medical records.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06353191

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

Recruiting
Not specifiedAges 18+Observational
Mayo Clinic
~693 participants
Updated 2026-08-18 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
3 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Collection of biospecimens from patients who developed cardiac toxicity (CRCT) or who are at high risk for developing CRCT
Measured over Baseline

Conditions

Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT06353191

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Arizona

    Scottsdale, Arizonastudy coordinator listed

    Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Floridastudy coordinator listed

    Recruiting

  • Moffitt Cancer Center

    Tampa, Floridastudy coordinator listed

    Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesotano site contact published

    Suspended

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Nadine Norton, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age or older
Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
One of the following:
Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
Completed chemotherapy with no cardiotoxicity at least two years post treatment
Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity
An understanding of the protocol and its requirements, risks, and discomforts
The ability and willingness to sign an informed consent

What this trial measures

  • Collection of biospecimens from patients who developed cardiac toxicity (CRCT) or who are at high risk for developing CRCTBaseline

    Assessed by the number of participants who participate and consent to have their specimen (blood draw) retained for future research.